✦ LIBER ✦

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

✍ Scribed by Soriano, A. O.; Yang, H.; Faderl, S.; Estrov, Z.; Giles, F.; Ravandi, F.; Cortes, J.; Wierda, W. G.; Ouzounian, S.; Quezada, A.; Pierce, S.; Estey, E. H.; Issa, J.-P. J.; Kantarjian, H. M.; Garcia-Manero, G.

Book ID: 125521172
Publisher: American Society of Hematology
Year: 2007
Tongue: English
Weight: 189 KB
Volume: 110
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2007-03-078576

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of poor-risk myelodysplastic s

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

✍ Andrea Kuendgen; Gesine Bug; Oliver G. Ottmann; Detlef Haase; Julie Schanz; Barb 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 195 KB

Clinical trial of valproic acid and all-

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

✍ Gesine Bug; Markus Ritter; Barbara Wassmann; Claudia Schoch; Thorsten Heinzel; K 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 2 views

## Abstract ## BACKGROUND Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all‐trans retinoic acid (ATRA). Clinical responses to VPA were recently observed in patients with myelodyspl

The combination of valproic acid, all-tr

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

✍ Fredly, Hanne; Ersvær, Elisabeth; Kittang, Astrid; Tsykunova, Galina; Gjertsen, 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 294 KB

Increase in platelet count in older, poo

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

✍ Chiara Pilatrino; Daniela Cilloni; Emanuela Messa; Alessandro Morotti; Emilia Gi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 772 KB

Combination of 5-azacytidine and thalido

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

✍ Azra Raza; Murtaza Mehdi; Muhammad Mumtaz; Fahad Ali; Steven Lascher; Naomi Gali 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Abstract ## BACKGROUND. The treatment of myelodysplastic syndromes (MDS) remains a challenge to the clinician despite recent advances. Many patients will either not respond or will have only limited and/or brief responses to single‐agent therapy. Eventually, 30% of patients with MDS will progre

The histone deacetylase (HDAC) inhibitor

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

✍ Andrea Kuendgen; Mathias Schmid; Richard Schlenk; Sabine Knipp; Barbara Hildebra 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

## Abstract ## BACKGROUND Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all‐trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro. ## METHODS We used VPA in 58 patients with acute myeloid leukemia (AML) who were too old a